SK Bioscience Co Ltd
KRX:302440
SK Bioscience Co Ltd
Cash from Operating Activities
SK Bioscience Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Cash from Operating Activities
-₩128B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Cash from Operating Activities
₩901.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Cash from Operating Activities
₩149.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
N
|
NatureCell Co Ltd
KOSDAQ:007390
|
Cash from Operating Activities
₩1.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
33%
|
CAGR 10-Years
29%
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Cash from Operating Activities
₩139.9B
|
CAGR 3-Years
29%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash from Operating Activities
₩53B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
42%
|
CAGR 10-Years
46%
|
|
SK Bioscience Co Ltd
Glance View
SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.
See Also
What is SK Bioscience Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
-128B
KRW
Based on the financial report for Dec 31, 2024, SK Bioscience Co Ltd's Cash from Operating Activities amounts to -128B KRW.
You don't have any saved screeners yet